Skip to content

The effect of Pyscalidine on lower back pain

The effect of Pyscalidine on lower back pain result from degenerative disc changes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017061234501N1
Enrollment
40
Registered
2017-08-23
Start date
2017-08-26
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower back pain result from degenerative disc changes. Loin pain, Low back strain, Lumbago NOS

Interventions

Intervention 1: Control group: In this group, non-steroidal anti-inflammatory drug will be prescribed within two months. Celecoxib 100 mg capsules, will be used every 12 hours (Orally). Interven
Treatment - Drugs
Control group: In this group, non-steroidal anti-inflammatory drug will be prescribed within two months. Celecoxib 100 mg capsules, will be used every 12 hours (Orally)
Intervention group: In this group, non-steroidal anti-inflammatory drug and also Piascledine will be prescribed within two months. Piascledine 300 mg capsules, once a day and Celecoxib 100 mg capsule

Sponsors

Ahvaz Jundishapur University Of Medical Sciences, Ahvaz, Iran
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age of 20- 60 years; having modic changes type one and two Identified by MRI; Patients’ pains have not been lasting for more than 6 months; the patient should not have surgical indication. Exclusion Criterion: Having diabetes

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The amount of pain. Timepoint: Before the intervention and two months after the intervention begins. Method of measurement: By VAS questionnaire.

Secondary

MeasureTime frame
Daily function of patients. Timepoint: Before the intervention and two months after the intervention begins. Method of measurement: Based on Roland Morris questionnaire.;Walking rate. Timepoint: Before the intervention and two months after the intervention begins. Method of measurement: Based on Roland Morris questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPardis Vakili

Ahvaz Jundishapur University Of Medical Sciences, Ahvaz, Iran

vakilipardis@yahoo.comvakili.p@ajums.ac.ir+98 61 3337 5717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026